The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.
Medicine Overview of Survanta 25mg/ml Intratracheal suspension
বাংলা
English
Indication
Resp distress syndrome (RDS) in premature infants.
Child Dose
Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency
Preferably w/in 15 mins of birth.
Rescue Preferably by 8 hr of age.
4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr.
Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.
Contraindication
None known.
Mode of Action
Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome.
Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.
Precaution
Infants <600 g birth wt. For intratracheal use only.
